Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Colorectal Neoplasms
• Mesothelioma
• Mesothelioma Malignant
• Mesothelioma Peritoneum
• Mesotheliomas Pleural
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Ovarian Neoplasms
• Ovarian Serous Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• TNBC - Triple-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TC-510

Snippet

Sponsor: TCR2 Therapeutics | Conditions: Mesothelioma, Mesotheliomas Pleural | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-13